Tudorza Pressair

Report
17 Pages
July 2018
Region: Global
Citeline
ID: 4775395

Drug Overview
Tudorza Pressair (aclidinium; AstraZeneca/Circassia/Kyorin Pharmaceutical) is a twice-daily long-acting muscarinic antagonist indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD)-associated bronchospasm, bronchitis, and emphysema. Tudorza Pressair received US and EU approvals for use in COPD in July 2012, and Japanese approval in March 2015. In Europe, the drug is marketed under the brand name Eklira Genuair.

OVERVIEW

Drug Overview
Product Profiles
Tudorza Pressair: Chronic obstructive pulmonary disease (COPD)

LIST OF FIGURES

Figure 1: Tudorza Pressair for COPD – SWOT analysis
Figure 2: The authors drug assessment summary of Tudorza Pressair for COPD
Figure 3: The authors drug assessment summary of Tudorza Pressair for COPD
Figure 4: Tudorza Pressair sales for COPD across the US, Japan, and major EU markets, by country, 2017–26

LIST OF TABLES

Table 1: Tudorza Pressair drug profile
Table 2: Tudorza Pressair Phase III data in COPD
Table 3: Tudorza Pressair sales for COPD across the US, Japan, and major EU markets, by country ($m), 2017–26

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€9713EUR$10,000USD£8,379GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€47592EUR$49,000USD£41,056GBP

Table of Contents

Related Topics

Related Reports

COPD in America 2023: Key Insights into Treatment Awareness & Satisfaction

COPD in America 2023: Understanding the COPD Patient Experience

Pulmonary Drugs - Global Market Insights, Competitive Landscape, and Market Forecast - 2028

Chronic Obstructive Pulmonary Disease (COPD) Treatment Global Market Report 2024

Anti-Asthmatics and COPD Drugs Global Market Report 2024